Duality Biotherapeutics (9606) H1 2025 earnings summary

Executive summary

• Revenue rose 22.9% year-over-year to RMB1,228.9 million for the six months ended June 30, 2025, mainly from out-licensing and collaboration agreements.

• Net loss increased to RMB2,073.9 million, primarily due to a one-time fair value loss on preferred shares conversion post-IPO.

• Completed Hong Kong IPO in April 2025, raising net proceeds of approximately HK$1,747.5 million and converting all preferred shares to ordinary shares.

• Advanced clinical pipeline with over 2,600 patients enrolled globally, FDA Fast Track for DB-1310, and multiple assets in late-stage development.

• Strategic partnerships expanded, including new collaborations with BioNTech, Avenzo, 3SBio, and other leading biopharma companies.

Financial highlights

• Revenue: RMB1,228.9 million, up 22.9% year-over-year, driven by licensing and collaboration income.

• Gross profit was RMB589.4 million, with a gross margin of 48.0% (down from 56.8% in prior year period).

• R&D expenses decreased to RMB349.4 million, mainly due to lower share-based compensation and no asset impairment.

• Administrative expenses increased to RMB125.5 million, reflecting listing-related costs.

• Net loss for the period was RMB2,073.9 million, up from RMB293.4 million, mainly due to a one-time fair value loss of RMB2,219.8 million on preferred shares.

• Adjusted profit (excluding fair value changes): RMB145.9 million, up 14.2% year-over-year.

• Cash and cash equivalents rose to RMB2,994.2 million as of June 30, 2025, boosted by IPO proceeds.

Outlook and guidance

• Sufficient funds to meet working capital and capital expenditure needs for the remainder of 2025.

• Plans to utilize remaining IPO proceeds over the next three to four years for R&D, clinical trials, commercialization, and platform development.

• Anticipates BLA and NDA filings for DB-1303/BNT323 in the US and China, respectively, in 2025.

• Focus on accelerating global development and commercialization of clinical-stage ADC programs.